The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and ...

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Dexcom was issued with an FDA warning letter after issues with “manufacturing processes and quality management systems.” ...

DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, Calif., and Mesa, Ariz. related to concerns about manufacturing ...

A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

Sitting before senators at his confirmation hearing to become commissioner of the FDA, Johns Hopkins surgeon and author ...

Almost 2.4 million Americans wear continuous glucose monitors, or CGMs, to track their blood sugar—and not all of them have ...